Matrix effect elimination during LC-MS/MS bioanalytical method development

被引:42
|
作者
Cote, Cynthia [1 ]
Bergeron, Annik [1 ]
Mess, Jean-Nicholas [1 ]
Furtado, Milton [1 ]
Garofolo, Fabio [1 ]
机构
[1] Algorithme Pharma Inc, Laval, PQ H7V 4B3, Canada
关键词
CHROMATOGRAPHY/TANDEM MASS-SPECTROMETRY; ATMOSPHERIC-PRESSURE PHOTOIONIZATION; LABELED INTERNAL STANDARD; SOLID-PHASE EXTRACTION; HUMAN PLASMA; QUANTITATIVE BIOANALYSIS; ELECTROSPRAY-IONIZATION; SAMPLE PREPARATION; STRUCTURAL ANALOG; LC/MS/MS ANALYSES;
D O I
10.4155/BIO.09.117
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Due to the presence of endogenous components in biofluids, ionization suppression or enhancement may occur for bioanalytical assays using LC-MS or LC-MS/MS technologies. The matrix effect may affect the precision and accuracy of a bioanalytical method and, therefore, compromise the quality of the results. Protein precipitation sample preparation along with LC-MS/MS is a high-throughput method most commonly used in bioanalysis and is largely affected by the matrix effect. In order to eliminate the matrix effect during the method development, some considerations may be used: cleaner sample preparations, more sensitive instruments, which allow less material to be injected, different chromatographic separations and much more must be investigated. More than giving tools to adequately assess the matrix effect during the method development, this review gives scientists numerous ways to eliminate or reduce the matrix effect based on novel sample-preparation techniques, new chromatographic optimization methods and new technologies.
引用
收藏
页码:1243 / 1257
页数:15
相关论文
共 50 条
  • [31] Alternative sample diluents in bioanalytical LC-MS
    David, Victor
    Cheregi, Mihaela
    Medvedovici, Andrei
    [J]. BIOANALYSIS, 2013, 5 (24) : 3051 - 3061
  • [32] BIOANALYTICAL METHOD DEVELOPMENT AND METHOD VALIDATION IN HUMAN PLASMA BY USING LC MS/MS
    Patil, Rahul
    Bhaskar, Rajveer
    Ola, Monika
    Pingale, Diksha
    Chalikwar, Shailesh
    [J]. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (03): : 5176 - 5183
  • [33] Development of LC-MS and LC-MS/MS Methods for Free Asparagine in Grains
    Chikasou, Masato
    Inohana, Syuichi
    Yokozeki, Toshiaki
    Tuchiya, Hitoshi
    Fujita, Kazuhiro
    [J]. FOOD HYGIENE AND SAFETY SCIENCE, 2018, 59 (05): : 248 - 256
  • [34] LC-MS/MS of Quetiapine: Elimination of Metabolite Interferences
    Morgan, P. E.
    Fisher, D. S.
    Flanagan, R. J.
    [J]. THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 643 - 643
  • [35] Recommendations for Validation of LC-MS/MS Bioanalytical Methods for Protein Biotherapeutics
    Jenkins, Rand
    Duggan, Jeffrey X.
    Aubry, Anne-Francoise
    Zeng, Jianing
    Lee, Jean W.
    Cojocaru, Laura
    Dufield, Dawn
    Garofolo, Fabio
    Kaur, Surinder
    Schultz, Gary A.
    Xu, Keyang
    Yang, Ziping
    Yu, John
    Zhang, Yan J.
    Vazvaei, Faye
    [J]. AAPS JOURNAL, 2015, 17 (01): : 1 - 16
  • [36] Recommendations for Validation of LC-MS/MS Bioanalytical Methods for Protein Biotherapeutics
    Rand Jenkins
    Jeffrey X. Duggan
    Anne-Françoise Aubry
    Jianing Zeng
    Jean W. Lee
    Laura Cojocaru
    Dawn Dufield
    Fabio Garofolo
    Surinder Kaur
    Gary A. Schultz
    Keyang Xu
    Ziping Yang
    John Yu
    Yan J. Zhang
    Faye Vazvaei
    [J]. The AAPS Journal, 2015, 17 : 1 - 16
  • [37] Development and validation of a LC-MS/MS method for salicylate analysis
    Yang, Lufang
    Rawluk, Cathy
    Ball, Gordon
    Hoag, Gordon
    [J]. CLINICAL BIOCHEMISTRY, 2016, 49 (18)
  • [38] Development of an LC-MS/MS method for aromatase inhibitor screening
    Myeong Hyeon Park
    In Sook Kim
    Mi-Sook Dong
    Hye Hyun Yoo
    [J]. Analytical and Bioanalytical Chemistry, 2014, 406 : 3443 - 3449
  • [39] Method development and validation of tranexamic acid by LC-MS/MS
    Ivica, Josko
    Gauthier, Jeannette
    Lamy, Andre
    Potter, Murray
    [J]. CLINICAL BIOCHEMISTRY, 2019, 74 : 90 - 90
  • [40] DEVELOPMENT OF LC-MS/MS REFERENCE METHOD FOR THE QUANTIFICATION OF LIPOPROTEIN(A)
    Marcovina, S. M.
    Vaisar, T.
    Clouet-Foraison, N.
    Hoofnagle, A.
    Koschinsky, M. L.
    Boffa, M. B.
    Lowenthal, M.
    [J]. ATHEROSCLEROSIS, 2021, 331 : E119 - E119